You are here: Urology Textbook > Bladder > Bladder cancer Symptoms and diagnosis
Bladder cancer: Symptoms, Diagnosis and Imaging
Review Literature: EAU guidelines superficial bladder cancer. EAU guidelines of muscle-invasive and metastatic bladder cancer. German S3 guidelines bladder carcinoma Harnblasenkarzinom.
- Bladder carcinoma: Definition, Epidemiology and Etiology
- Bladder carcinoma: Pathology and TNM tumor stages
- Bladder carcinoma: Symptoms and Diagnosis
- Bladder carcinoma: Surgical Treatment
- Bladder carcinoma: Chemotherapy and Immunotherapy of Metastases
Signs and Symptoms of Bladder Cancer
Symptoms of Superficial Bladder Carcinoma:
Painless hematuria, rather intermittently, is the leading symptom (85–90%). Irritative symptoms like dysuria, frequency and urgency are not as common (30%). Most of the superficial bladder cancers are symptomatic.
Signs and Symptoms of Advanced Bladder Cancer:
Abdominal mass, bone pain, flank pain, hydronephrosis, weight loss, night sweats.
Diagnostic Work-Up of Bladder Cancer
Microhematuria or macrohematuria.
Microscopic examination of exfoliated urothelial cells of the urine can reliably identify G2 and G3 cells of bladder carcinoma. Cells of well-differentiated tumors are less often exfoliated and are harder to distinguis from cells of inflammatory lesions.
Urine markers improve the detection of bladder cancer and may reduce the frequency of cystoscopy in the follow-up of superficial tumors. The exact role of urine markers in the diagnostic work-up is unclear, see Tab. sensitivity and specificity of urine markers and section experimental diagnostics.
Blood count may reveal a hypochromic anemia and iron deficiency due to chronic bleeding. Tumor anemia is possible in advanced disease. Elevated liver encymes are a symptom of liver metastasis. Hydronephrosis may cause elevated creatinine and urea serum concentrations. Elevated AP is caused by bone metastases.
Imaging of Bladder Cancer
Intravenous Pyelography (IVP):
IVP is indicated to rule out upper tract anomalies, which may be a sign of upper tract urothelial carcinoma or hydronephrosis due to invasive bladder cancer. If invasive bladder cancer is suspected, intravenous urography should be replaced by an CT abdomen. Bladder tumor may be seen in the bladder filled with contrast media. [fig. IVP of an advanced bladder cancer].
Ultrasound imaging is done with a full bladder. Bladder cancer appears as echogenic mass that protrudes into the lumen [fig. ultrasound imaging of bladder cancer]. Invasive bladder cancer may be suspected, if the normally highly echogenic bladder wall is interrupted by less echogenic tissue from the bladder tumor (false-negativ 40%, false-positive in 10%).
Ultrasonography of the kidneys is done to detect hydronephrosis or a mass in the renal sinus as signs for upper tract urothelial cancer.
Staging of invasive bladder cancer:
CT or MRI of the abdomen is suited to stage advanced bladder cancer, in particular to detect visceral metastases or large lymph node metastates [fig. CT abdomen of an advanced bladder cancer]. An CT scan with excretory phase and opacification of the urinary collecting system is necessary for adequate imaging to detect a secondary carcinoma of the upper urinary tract. Local tumor stage or small lymph node metastases are not reliable detectable with both imaging techniques.
Further necessary imaging:
- Chest X-ray or CT thorax is done to detect pulmonary metastases
- Bone scintigraph
- ultrasound imaging of the liver, if abdominal imaging with CT or MRI has not been done
Cystoscopy and transurethral resection of the bladder (TURB)
Cystoscopy is the single most important procedure to diagnose bladder tumors. The location, size and appearance of the tumor is documented. Bladder tumors or suspicious tissue are treated by transurethral resection of the bladder (see section TURB) with deep resection into the tunica muscularis [fig. TURB]. Quadrant biopsy of the urinary bladder is a diagnostic procedure for patients with suspected high-grade bladder carcinoma (e.g., history of high grade tumor or urinary cytology with high-grade cells): small samples are taken from the anterior wall, the two side walls, the posterior bladder wall and prostatic urethra.
Standard cystoscopy is not able to visualize all forms of bladder carcinoma. Especially flat high-grade lesions may be overseen or may look like normal urothelium. The fluorescence cystoscopy improves the detection of CIS by 25–30%. The bladder is incubated for 1 h with hexaminolevulinate (HAL) and the cystoscopy is done with blue light (375–440 nm wave length). Hexaminolevulinate is a photosensitive porphyrin which accumulates preferentially in tissue with a high turn-over of cells like neoplastic tissues but also in inflammatory lesions. Tissues with a high concentration of HAL glow red under blue light. Clinically relevant improvement in sensitivity and specificity has been proved in several randomized trials (Jocham et al., 2005).
Experimental Diagnostic Techniques
Urine markers for the diagnosis of bladder cancer: urinary bladder cancer antigen (UBC), BTA stat, nuclear matrix protein (NMP22), telomerase, survivin, multi-target FISH (UroVysion), loss of chromosomes. No marker has sufficient sensitivity and specificity to replace cystoscopy or urine cytology.
Urine immunocytology improves the results of standard urine cytology. Detection of cytokeratin in serum or bone marrow with the help of PCR correlates with an advanced tumor stage.
Differential Diagnosis of Bladder Tumors
- Inflammation or infection
- Tissue reaction due to foreign bodies (DK, bladder stones)
- Bladder fistula (birth trauma, diverticulitis, Crohn disease, rectal cancer)
- Benign and malignant bladder tumors: see section pathology
|Bladder cancer: pathology||Index||Bladder cancer treatment|
Index: 1–9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Infection: is it a cause of bladder
Scand J Urol Nephrol Suppl, 2008, 79-84.
Amin und Young 1997 AMIN, M. B. ; YOUNG, R. H.:
Primary carcinomas of the urethra.
In: Semin Diagn Pathol
14 (1997), Nr. 2, S. 147–60
Babjuk, M.; Burger, M.; Compérat, E.; Gonter, P.;
Mostafid, A.; Palou, J.; van Rhijn, B.; Rouprêt, M.; Shariata, S.;
Sylvester, R. & Zigeuner, R.
Non-muscle-invasive Bladder CancerEAU Guidelines, 2020 http://uroweb.org/guideline/non-muscle-invasive-bladder-cancer/
Brinkman, M. & Zeegers, M. P.
fluid and bladder cancer.
Scand J Urol Nephrol Suppl, 2008, 25-36.
Cohn, J. A.; Vekhter, B.; Lyttle, C.; Steinberg,
G. D. & Large, M. C.
Sex disparities in diagnosis of bladder cancer
after initial presentation with hematuria: a nationwide claims-based
Cancer, 2014, 120, 555-561
DGU; DKG; DKG & Leitlinienprogramm Onkologie S3-Leitlinie (Langfassung): Früherkennung, Diagnose, Therapie und Nachsorge des Harnblasenkarzinoms. http://www.leitlinienprogramm-onkologie.de/leitlinien/harnblasenkarzinom/
Helpap und Kollermann 2000 HELPAP, B. ;
[Revisions in the WHO histological classification of urothelial
bladder tumors and flat urothelial lesions].
21 (2000), Nr. 3, S. 211–7
IARC (2004) Monographs on the Evaluation of Carcinogenic Risks to Humans. Volume 83. Tobacco Smoke and Involuntary Smoking. World Health Organization.
Kalble 2001 KALBLE, T.:
[Etiopathology, risk factors, environmental influences and
epidemiology of bladder cancer].
In: Urologe A
40 (2001), Nr. 6, S. 447–50
Kataja und Pavlidis 2005 KATAJA, V. V. ;
ESMO Minimum Clinical Recommendations for diagnosis, treatment and
follow-up of invasive bladder cancer.
In: Ann Oncol
16 Suppl 1 (2005), S. i43–4
Krieg und Hoffman 1999 KRIEG, R. ; HOFFMAN, R.:
Current management of unusual genitourinary cancers. Part 2: Urethral
In: Oncology (Williston Park)
13 (1999), Nr. 11, S. 1511–7, 1520; discussion 1523–4
Lammers, R. J. M.; Witjes, W. P. J.; Hendricksen, K.;
Caris, C. T. M.; Janzing-Pastors, M. H. C. & Witjes, J. A.
status is a risk factor for recurrence after transurethral resection of
non-muscle-invasive bladder cancer.
Eur Urol, 2011, 60, 713-720
Lampel und Thuroff 1998a LAMPEL, A. ;
THUROFF, J. W.:
[Bladder carcinoma 1: Radical cystectomy, neoadjuvant and adjuvant
In: Urologe A
37 (1998), Nr. 1, S. 93–101
Lampel und Thuroff 1998b LAMPEL, A. ;
THUROFF, J. W.:
[Bladder carcinoma. 2: Urinary diversion].
In: Urologe A
37 (1998), Nr. 2, S. W207–20
Leppert u.a. 2006 LEPPERT, J. T. ; SHVARTS,
O. ; KAWAOKA, K. ; LIEBERMAN, R. ; BELLDEGRUN,
A. S. ; PANTUCK, A. J.:
Prevention of bladder cancer: a review.
In: Eur Urol
49 (2006), Nr. 2, S. 226–34
Liu, S.; Yang, T.; Na, R.; Hu, M.; Zhang, L.; Fu,
Y.; Jiang, H. & Ding, Q.
The impact of female gender on bladder cancer-specific death risk after radical cystectomy: a meta-analysis of 27,912 patients. International urology and nephrology, 2015, 47, 951-958
Michaud u.a. 1999 MICHAUD, D. S. ; SPIEGELMAN,
D. ; CLINTON, S. K. ; RIMM, E. B. ; CURHAN,
G. C. ; WILLETT, W. C. ; GIOVANNUCCI, E. L.:
Fluid intake and the risk of bladder cancer in men.
In: N Engl J Med
340 (1999), Nr. 18, S. 1390–7
Plna und Hemminki 2001 PLNA, K. ; HEMMINKI, K.:
Familial bladder cancer in the National Swedish Family Cancer
In: J Urol
166 (2001), Nr. 6, S. 2129–33
Rajan u.a. 1993 RAJAN, N. ; TUCCI, P. ;
MALLOUH, C. ; CHOUDHURY, M.:
Carcinoma in female urethral diverticulum: case reports and review of
In: J Urol
150 (1993), Nr. 6, S. 1911–4
Robert-Koch-Institut (2015) Krebs in Deutschland 2011/2012. www.krebsdaten.de
Stein u.a. 2001 STEIN, J. P. ; LIESKOVSKY,
G. ; COTE, R. ; GROSHEN, S. ; FENG, A. C. ;
BOYD, S. ; SKINNER, E. ; BOCHNER, B. ;
THANGATHURAI, D. ; MIKHAIL, M. ; RAGHAVAN, D. ;
SKINNER, D. G.:
Radical cystectomy in the treatment of invasive bladder cancer:
long-term results in 1054 patients.
In: J Clin Oncol
19 (2001), Nr. 3, S. 666–75
Weissbach 2001 WEISSBACH, L.:
[Palliation of urothelial carcinoma of the bladder].
In: Urologe A
40 (2001), Nr. 6, S. 475–9
Witjes, J.; Compérat, E.; Cowan, N.; Gakis, G.;
Hernánde, V.; Lebret, T.; Lorch, A.; van der Heijden, A. & Ribal, M.
and Metastatic Bladder Cancer
EAU Guidelines, 2020 http://uroweb.org/guideline/bladder-cancer-muscle-invasive-and-metastatic/
Deutsche Version: Symptome und Diagnose des Harnblasenkarzinoms